Overview

L-PZQ ODT in Schistosoma Infected Children

Status:
Completed

Trial end date:
2021-10-11

Target enrollment:

Participant gender:

Summary

The study will evaluate the safety and efficacy of L-praziquantel orodispersible (L-PZQ ODT) tablets in Schistosoma infected children aged 3 months to 6 years.

Phase:

Phase 3

Details

Lead Sponsor:

Merck KGaA, Darmstadt, Germany

Treatments:

Praziquantel